| Schedule of Non-Controlling Interests in Consolidated Entities |
Non-controlling interests in consolidated entities are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended |
|
|
|
|
|
|
|
|
As of March 31, 2021 |
|
March 31, 2021 |
|
As of March 31, 2021 |
|
|
|
|
|
|
|
|
Net loss attributable to |
|
Non-controlling interests |
|
Non-controlling |
|
($ in thousands) |
|
NCI equity share |
|
non-controlling interests |
|
in consolidated entities |
|
ownership |
|
FBIO Acquisition Corp VIII |
|
$ |
(99) |
|
|
(28) |
|
$ |
(127) |
|
24.0 |
% |
Aevitas |
|
|
(3,874) |
|
|
(318) |
|
|
(4,192) |
|
46.0 |
% |
Avenue 2 |
|
|
1,915 |
|
|
(773) |
|
|
1,142 |
|
77.4 |
% |
Baergic |
|
|
(1,838) |
|
|
(12) |
|
|
(1,850) |
|
39.5 |
% |
Cellvation |
|
|
(1,313) |
|
|
(39) |
|
|
(1,352) |
|
22.1 |
% |
Checkpoint 1 |
|
|
48,130 |
|
|
(4,588) |
|
|
43,542 |
|
80.4 |
% |
Coronado SO |
|
|
(290) |
|
|
— |
|
|
(290) |
|
13.0 |
% |
Cyprium |
|
|
(1,033) |
|
|
(478) |
|
|
(1,511) |
|
29.8 |
% |
Helocyte |
|
|
(5,210) |
|
|
(53) |
|
|
(5,263) |
|
18.3 |
% |
JMC |
|
|
1,076 |
|
|
35 |
|
|
1,111 |
|
12.0 |
% |
Mustang 2 |
|
|
119,322 |
|
|
(10,862) |
|
|
108,460 |
|
81.3 |
% |
Oncogenuity |
|
|
(507) |
|
|
(128) |
|
|
(635) |
|
25.3 |
% |
Tamid |
|
|
(712) |
|
|
— |
|
|
(712) |
|
22.8 |
% |
Total |
|
$ |
155,567 |
|
$ |
(17,244) |
|
$ |
138,323 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the twelve months ended |
|
|
|
|
|
|
|
|
As of December 31, 2020 |
|
December 31, 2020 |
|
As of December 31, 2020 |
|
|
|
|
|
|
|
|
Net loss attributable to |
|
Non-controlling interests |
|
Non-controlling |
|
($ in thousands) |
|
NCI equity share |
|
non-controlling interests |
|
in consolidated entities |
|
ownership |
|
FBIO Acquisition Corp VIII |
|
$ |
(7) |
|
|
(27) |
|
$ |
(34) |
|
10.0 |
% |
Aevitas |
|
|
(2,370) |
|
|
(823) |
|
|
(3,193) |
|
39.0 |
% |
Avenue 2 |
|
|
5,800 |
|
|
(3,974) |
|
|
1,826 |
|
77.4 |
% |
Baergic |
|
|
(1,662) |
|
|
(97) |
|
|
(1,759) |
|
39.5 |
% |
Cellvation |
|
|
(1,089) |
|
|
(182) |
|
|
(1,271) |
|
22.1 |
% |
Checkpoint 1 |
|
|
41,704 |
|
|
(13,265) |
|
|
28,439 |
|
80.4 |
% |
Coronado SO |
|
|
(290) |
|
|
— |
|
|
(290) |
|
13.0 |
% |
Cyprium |
|
|
567 |
|
|
(1,478) |
|
|
(911) |
|
30.5 |
% |
Helocyte |
|
|
(4,986) |
|
|
(259) |
|
|
(5,245) |
|
18.8 |
% |
JMC |
|
|
138 |
|
|
491 |
|
|
629 |
|
7.1 |
% |
Mustang 2 |
|
|
116,060 |
|
|
(36,429) |
|
|
79,631 |
|
80.9 |
% |
Oncogenuity |
|
|
(82) |
|
|
(376) |
|
|
(458) |
|
25.3 |
% |
Tamid |
|
|
(663) |
|
|
(40) |
|
|
(703) |
|
22.8 |
% |
Total |
|
$ |
153,120 |
|
$ |
(56,459) |
|
$ |
96,661 |
|
|
|
Note 1: |
Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights. |
Note 2: |
Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights. |
|